Compare Stocks

→ Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HEB Hemispherx BioPharma	$0.43	$0.00	$1.69 ▼ $14.81	$1.05M	N/A	102,599 shs	160,867 shs
VAL Valaris	$67.26 -0.3%	$69.52	$54.13 ▼ $78.92	$4.87B	1.13	869,104 shs	220,098 shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
VAL Valaris	-2.37%	-0.69%	-6.32%	-1.45%	+11.94%

Mysterious Gold Leverage Just Announced (Ad)

World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.

Find out what it is and see how you can get in with just a few dollars.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VAL Valaris	3.5935 of 5 stars	3.5	2.0	0.0	0.0	2.8	1.7	3.1

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A
VAL Valaris	3.00	Buy	$100.00	48.68% Upside

Current Analyst Ratings

Latest HEB, SALV, PYC, and VAL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/5/2024	VAL Valaris	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$105.00 ➝ $102.00
2/23/2024	VAL Valaris	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$107.00 ➝ $105.00
2/14/2024	VAL Valaris	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$106.00 ➝ $105.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A
VAL Valaris	$1.78B	2.73	$2.46 per share	27.37	$27.40 per share	2.45

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HEB Hemispherx BioPharma	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VAL Valaris	$865.40M	$11.69	5.75	6.48	N/A	48.50%	5.71%	2.40%	5/2/2024 (Confirmed)

Latest HEB, SALV, PYC, and VAL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/2/2024	N/A	VAL Valaris	$0.40	N/A	-$0.40	N/A	N/A	N/A
2/21/2024	Q4 2023	VAL Valaris	$0.29	$0.61	+$0.32	-$10.08	$484.00 million	$483.80 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A	N/A
VAL Valaris	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HEB Hemispherx BioPharma	N/A	N/A	N/A
VAL Valaris	0.54	1.71	1.71

Ownership

Institutional Ownership

Company	Institutional Ownership
HEB Hemispherx BioPharma	N/A
VAL Valaris	96.74%

Insider Ownership

Company	Insider Ownership
HEB Hemispherx BioPharma	N/A
VAL Valaris	0.11%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
HEB Hemispherx BioPharma	31	2.44 million	N/A	Not Optionable
VAL Valaris	5,985	72.41 million	72.33 million	Optionable

HEB, SALV, PYC, and VAL Headlines

Source	Headline
	Equinor rolls up its sleeves for imminent Argentina exploration well upstreamonline.com - April 25 at 9:14 AM
	Valaris (VAL) Set to Announce Quarterly Earnings on Thursday americanbankingnews.com - April 25 at 2:32 AM
	Louisiana State Employees Retirement System Takes $1.21 Million Position in Valaris Limited (NYSE:VAL) marketbeat.com - April 23 at 4:51 AM
	John Fredriksen ally wins seat on board of potential takeover target International Seaways tradewindsnews.com - April 18 at 10:48 PM
	Valaris Limited (NYSE:VAL) Shares Sold by River Road Asset Management LLC marketbeat.com - April 18 at 9:34 AM
	Interocean announces UT technology demonstration zawya.com - April 16 at 8:33 AM
	Mutual of America Capital Management LLC Acquires 38,367 Shares of Valaris Limited (NYSE:VAL) marketbeat.com - April 14 at 6:11 AM
	Valaris Schedules First Quarter 2024 Earnings Release and Conference Call businesswire.com - April 11 at 4:30 PM
	Aramco Suspends Valaris Rig Contract rigzone.com - April 11 at 1:38 AM
	Valaris (VAL) Receives Rig's Suspension Notice From Aramco zacks.com - April 9 at 2:26 PM
	Lancaster Investment Management Buys Shares of 400,116 Valaris Limited (NYSE:VAL) marketbeat.com - April 9 at 12:12 PM
	Port Everglades marks commissioning of new container cranes en.portnews.ru - April 7 at 11:30 AM
	Valaris faces rig suspension in Saudi joint venture investing.com - April 6 at 2:41 AM
	Aramco Suspends Another Jack-Up Rig oedigital.com - April 5 at 4:40 PM
	Suspension notice for Valaris joint venture royalgazette.com - April 5 at 4:40 PM
	Saudi Aramco suspends offshore rig deal with New York-listed player upstreamonline.com - April 5 at 1:44 AM
	Aramco suspends jackup contract with offshore driller upstreamonline.com - April 4 at 8:43 PM
	Valaris (NYSE:VAL) Shares Gap Down to $76.66 marketbeat.com - April 4 at 2:02 PM
	Valaris Limited (NYSE:VAL) Shares Purchased by Vanguard Group Inc. marketbeat.com - April 3 at 4:09 AM
	Valaris: Buy Despite Near-Term Jackup Market Headwinds seekingalpha.com - April 2 at 7:31 PM
	VAL Quantitative Stock Analysis nasdaq.com - April 1 at 6:26 PM
	Valaris Limited (NYSE:VAL) Receives Consensus Recommendation of "Buy" from Analysts marketbeat.com - April 1 at 4:14 AM
	Four-way race in heated Petrobras tender for well intervention vessels upstreamonline.com - March 28 at 4:58 PM
	Esgian Week 12 Report: New Finds in Guyana, China and Norway marinelink.com - March 24 at 9:59 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Wall Street tumbles after dispiriting data on the economy, as Meta sinks
April 25, 2024 2:14 AM
View Stock market today: Wall Street tumbles after dispiriting data on the economy, as Meta sinks
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
ASML’s Earnings Could Bring The Stock to New Highs
April 16, 2024 10:20 AM
View ASML’s Earnings Could Bring The Stock to New Highs

All Headlines

Company Descriptions

Hemispherx BioPharma

NYSEAMERICAN:HEB

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

Valaris

NYSE:VAL

Valaris Limited, together with its subsidiaries, provides offshore contract drilling services Gulf of Mexico, South America, North Sea, the Middle East, Africa, and the Asia Pacific. The company operates through four segments: Floaters, Jackups, ARO, and Other. It owns an offshore drilling rig fleet, which include drillships, dynamically positioned semisubmersible rigs, moored semisubmersible rig, and jackup rigs. It serves international, government-owned, and independent oil and gas. Valaris Limited was founded in 1975 and is based in Hamilton, Bermuda.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial